Clinical trials: Overweight and/or Obesity
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA)…
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
- Trial name
- TRIUMPH-1 (NCT05929066)
- Testing
- Retatrutide
- Where
- 134 sites in United States, Australia and 10 more
- Volunteers
- 2,335 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus
- Trial name
- NCT05669599
- Testing
- Maridebart Cafraglutide
- Where
- 78 sites in United States, Australia and 10 more
- Volunteers
- 592 people
- Sponsor
- Amgen
Obesity, Overweight and/or Obesity
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight
- Trial name
- NCT07595549
- Testing
- PF-08653944
- Where
- 72 sites in United States, Brazil and 9 more
- Volunteers
- 954 people
- Sponsor
- Pfizer
Obesity, Dyslipidemias
European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia
Primary : To determine the effect of Rimonabant 20 mg on changes in, HDL-Cholesterol (HDL-C), triglyceride levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with…
- Trial name
- ETERNAL (NCT00412698)
- Testing
- rimonabant
- Where
- 15 sites in Czechia, Finland and 13 more
- Volunteers
- 645 people
- Sponsor
- Sanofi
Overweight or Obesity
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes.
- Trial name
- NCT07690826
- Testing
- HRS-4729 Injection, HRS-4729 Injection;
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Overweight or Obese, Obesity and Overweight
A Trial With EMP16 in Preparation for Late Phase Studies
The goal of this clinical trial is to explore the impact of dietary fibre supplement in the form of Vi-Siblin® S (ispaghula seed coats), together with advice on proper healthy diet, on tolerability during dose-escalation of EMP16…
- Trial name
- POEM (NCT06993428)
- Testing
- EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mg, Vi-Siblin® S
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Obesity
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected)…
- Trial name
- NCT07225816
- Testing
- Liraglutide, Oral Semaglutide, Semaglutide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Infant Nutrition
Effect of Formula on Growth of Infants From Overweight or Obese Mothers
The purpose of this study is to determine whether infants, from overweight or obese mothers, fed a formula with proteins and calories different than a standard infant formula have a different growth
- Trial name
- NCT00820833
- Testing
- standard infant formula, Test formula
- Where
- Chile
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Overweight or Obesity
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HRS-7535 tablet in obese subjects.
- Trial name
- NCT06621316
- Testing
- HRS-7535 Tablet
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®).
- Trial name
- COURAGE (NCT06299098)
- Testing
- Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight and/or Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
- Trial name
- NCT07876518
- Testing
- PF-08656795
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.
- Trial name
- NCT06934408
- Testing
- HRS-5817 Injection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite.
- Trial name
- NCT05363774
- Testing
- NNC0519-0130
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Obesity and Overweight
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity
The goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity.
- Trial name
- NCT06857617
- Testing
- (Part C) MET097
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Metsera, a wholly owned subsidiary of Pfizer
Obesity, Behavior, Health
Coached or Non-Coached Weight Loss Intervention
To evaluate the effect of one-on-one coaching in the Noom Healthy Weight Program, a digital behavior change, weight loss intervention, compared to the same program with no coaching, as well as influential factors.
- Conditions
- Obesity, Behavior, Health, Behavior, Eating, Weight Loss
- Trial name
- NCT04645108
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching, Noom Healthy Weight; mobile behavior change program for weight loss
- Where
- United States
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Overweight or Obesity
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
- Trial name
- NCT06830343
- Testing
- SYH9017, Wegovy ®
- Where
- China
- Volunteers
- 66 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Obesity, Overweight
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure.
- Conditions
- Obesity, Overweight, Obstructive Sleep Apnoea
- Trial name
- AMAZE 4 (NCT07571109)
- Testing
- NNC0487-0111
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Healthy, Overweight and Obese Adults
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
- Trial name
- NCT07307274
- Testing
- SYNT101
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Syntis Bio